Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • Europe
  • 350 Pages
  • No of Tables: 91
  • No of Figures: 43

Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs (Prolastin, Zemaira/Respreeza, Glassia, Aralast NP, and Others), Gene Type (Type PiZZ, Type PiMS, Type PiMZ, and Others), Application (Lung Disease and Liver Disease), Population Type (Adults and Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) Industry Trends and Forecast to 2029.

Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Analysis and Insights 

Alpha-1 antitrypsin deficiency (AATD) is the condition that occurs when the liver fails to secrete a protein called alpha-1 antitrypsin that must be released into the blood-stream for various functions such as protecting tissues in the body from being attacked by body’s secreted enzymes. This genetic condition can progress to lung or liver diseases if left untreated. Most patients with this deficiency will either have less protein or do not produce the protein at all and therefore lose its function, leading to abnormal protein produced within the liver cells, causing liver injury.

Augmentation therapy is the only specific treatment licensed for patients with AATD associated lung disease. The therapy uses alpha-1 antitrypsin protein derived from the blood of healthy donors to increase the amount of the protein in the lungs of AAT deficiency patients. This therapy is also called replacement therapy, though it can’t reverse the lung damage that has already occurred but can slow down the further deterioration of lung function. The protein is usually given through an intravenous route with needle insertion.

Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is expected to reach USD 317.65 million by 2029 from USD 179.24 million in 2021, growing with a CAGR of 8.3% in the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Price in USD

Segments Covered

By Drugs (Prolastin, Aralast NP, Zemaira/Respreeza, Glassia And Others), Gene Type (Type Pimz, Type Pims, Type Pizz And Others), Application (Lung Disease And Liver Disease), Population Type (Adults And Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, And Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy And Others)

Countries Covered

Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey and Rest of Europe

Market Players Covered

Grifols, S.A. (Spain), CSL, Kamada Pharmaceuticals., Takeda Pharmaceutical Company Limited., and LFB BIOMEDICAMENTS. The Pipeline companies which are dealing in market includes Arrowhead Pharmaceuticals, Inc., Mereo BioPharma Group plc, Inhibrx, Inc., Centessa Pharmaceuticals (Z Factor)., Intellia Therapeutics, Inc., Apic Bio, Krystal Biotech, Beam Therapeutics, and LOGICBIO THERAPEUTICS, INC., among others

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics

Drivers

  • Rise in Incidence and Prevalence of AATD

With the increase prevalence and incidence of AATD worldwide, there is an increase in the demand for effective therapy products which will increase in upcoming years. Therefore, rising incidences are expected to act as a driver for the growth of the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.

  • Wide Range of Risks And Comorbidities with AATD

Another significant factor influencing the growth rate of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is the wide range of risks and comorbidities with AATD. External factors such ach smoking and alcohol consumption also affect severe outcomes directly. Progressive risk to live and lung health will aid the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.

  • Improving Diagnostic Techniques for Genetic Disorders

Growing prevalence of alpha-1 antitrypsin deficiency (AATD) in various regions worldwide and various infections associated with it are expected to act as drivers for development in rare disease diagnostics. Accurate and reliable diagnosis can lead to better quality of life for patients and hence the growth of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.

Furthermore, improved technology for production and purification methods of AAT, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. 

Opportunities

  • Growing R & D Activities

The Europe food and drug has approved several products currently available in the United States to treat emphysema in patients with AATD. However complete cure for alpha-1 antitrypsin deficiency (AATD) does not exist and hence gives way for new research and opportunity for development of better more effective therapies.

Also, the strategic initiatives by key players and rise in healthcare expenditure will provide structural integrity and future opportunities for the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in the forecast period of 2022-2029.

Restraints/Challenges

However, high cost of therapies and side effects and complications of augmentation therapies will impede the growth rate of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Additionally, difficulty in specific identification and stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on alpha-1 antitrypsin deficiency (AATD) augmentation therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in sepsis medication adherence during the pandemic.

Recent Development

  • In October, 2020, Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc. to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD).

The Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Scope

The Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy market is segmented into techniques and test type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Drugs

  • Prolastin
  • Aralast NP
  • Zemaira/Respreeza
  • Glassia
  • Others

On the basis of drugs, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into prolastin, aralast NP, zemaira/respreeza, glassia and others.   

Gene Type

  • Type PIMZ
  • Type PIMS
  • Type PIZZ
  • Others

On the basis of gene type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into type PiMZ, type PiMS, type PiZZ and others.

Application

  • Lung Disease
  • Liver Disease

On the basis of application, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into lung disease and liver disease.

Population Type

  • Adults
  • Pediatric

On the basis of population type, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into adults and pediatric.

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

On the basis of end user, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Regional Analysis/Insights     

The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is analysed and market size insights and trends are provided by country, drugs, gene type, population type, application, end user and distribution channel as referenced above.

The countries covered in the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report are Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey and Rest of Europe.

Germany dominates the Europe alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing healthcare expenditure in Germany, remaining at the highest level among European Union member states, is further improving the country’s market growth.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Share Analysis

The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.

Some of the major players operating in the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market are Grifols, S.A. (Spain), CSL, Kamada Pharmaceuticals., Takeda Pharmaceutical Company Limited., and LFB BIOMEDICAMENTS. The Pipeline companies which are dealing in market includes Arrowhead Pharmaceuticals, Inc., Mereo BioPharma Group plc, Inhibrx, Inc., Centessa Pharmaceuticals (Z Factor)., Intellia Therapeutics, Inc., Apic Bio, Krystal Biotech, Beam Therapeutics, and LOGICBIO THERAPEUTICS, INC., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available: Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 5 U.S. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 6 U.S. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 11 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 12 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 13 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 17 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 19 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 20 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 21 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 GERMANY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 23 GERMANY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 25 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 28 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 29 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 U.K. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 U.K. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 33 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 36 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 37 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 FRANCE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 39 FRANCE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 41 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 42 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 43 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 44 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 45 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 ITALY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 ITALY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 48 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 49 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 51 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 52 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 53 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 54 SPAIN LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SPAIN LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 57 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 60 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 61 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 NETHERLANDS LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 NETHERLANDS LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 64 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 65 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 66 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 67 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 68 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 69 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 SWITZERLAND LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 SWITZERLAND LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 73 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 76 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 77 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 78 RUSSIA LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 79 RUSSIA LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 80 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 81 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 84 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 85 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 TURKEY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 TURKEY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 88 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 89 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 REST OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions